In the harsh economic climate that has prevailed in the past couple of years, it’s hard to imagine any successful pharmaceutical leader willingly wanting to enter the unpredictable world of startups. But that’s just the course Christine Bunt, the German-born chief operating officer of Taris Biomedical, has chosen.
To some it might appear that the opportunity to lead the specialty pharmaceutical company, which is focused on local minimally invasive drug-device convergence products, was divine intervention.
After a successful career with two of the industry’s most respected pharmaceutical companies, several familial relocations, and an appreciation and understanding of the necessity to converge drugs and devices to address unmet needs, Ms. Bunt was in the right place at the right time to take the helm of Taris, whose name…
Taris’ Therapeutic Areas
Therapeutic Areas/Patient Distribution
Honing the Focus